Kiichiro Tsutani
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kiichiro Tsutani.
Health Economics | 2010
Takeru Shiroiwa; Yoon-Kyoung Sung; Takashi Fukuda; Hui-Chu Lang; Sang-Cheol Bae; Kiichiro Tsutani
Although the threshold of cost effectiveness of medical interventions is thought to be 20 000- 30 000 UK pounds in the UK, and
American Journal of Geriatric Pharmacotherapy | 2010
Manabu Akazawa; Hirohisa Imai; Ataru Igarashi; Kiichiro Tsutani
50 000-
Journal of Epidemiology | 2010
Hiroharu Kamioka; Kiichiro Tsutani; Hiroyasu Okuizumi; Yoshiteru Mutoh; Miho Ohta; Shuichi Handa; Shinpei Okada; Jun Kitayuguchi; Masamitsu Kamada; Nobuyoshi Shiozawa; Takuya Honda
100 000 in the US, it is well known that these values are unjustified, due to lack of explicit scientific evidence. We measured willingness-to-pay (WTP) for one additional quality-adjusted life-year gained to determine the threshold of the incremental cost-effectiveness ratio. Our study used the Internet to compare WTP for the additional year of survival in a perfect status of health in Japan, the Republic of Korea (ROK), Taiwan, Australia, the UK, and the US. The research utilized a double-bound dichotomous choice, and analysis by the nonparametric Turnbull method. WTP values were JPY 5 million (Japan), KWN 68 million (ROK), NT
Chinese Journal of Integrative Medicine | 2011
Yoshiharu Motoo; Takashi Seki; Kiichiro Tsutani
2.1 million (Taiwan), 23 000 UK pounds (UK), AU
Journal of Clinical Pharmacy and Therapeutics | 2010
Kaori Tsuji; Kiichiro Tsutani
64 000 (Australia), and US
Patient Preference and Adherence | 2014
Hiroharu Kamioka; Kiichiro Tsutani; Minoru Yamada; Hyuntae Park; Hiroyasu Okuizumi; Koki Tsuruoka; Takuya Honda; Shinpei Okada; Sang-Jun Park; Jun Kitayuguchi; Takafumi Abe; Shuichi Handa; Takuya Oshio; Yoshiteru Mutoh
62 000 (US). The discount rates of outcome were estimated at 6.8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making.
Molecular Diagnosis & Therapy | 2010
Takeru Shiroiwa; Yoshiharu Motoo; Kiichiro Tsutani
BACKGROUND Modified Beers criteria for elderly Japanese patients were developed in 2008 by consensus among 9 experts to reflect regional clinical practice and available medications in Japan. Since then, many physicians and pharmacists have expressed interest in obtaining more information about the criteria and alternative drug choices. OBJECTIVE This study examined the incidence, health care utilization, and costs associated with potentially inappropriate medications (PIMs) in elderly patients based on the modified Beers criteria. METHODS A retrospective, observational cohort study was conducted using health insurance claims data in Japan. The study population included elderly patients aged >or=65 years who had at least 2 pharmacy claims in separate months over a 1-year period (April 2006 through March 2007). Use of the PIMs was identified using the modified criteria, and 1-year incidence rates were calculated for the total study population and for subgroups stratified by age and sex. A logistic regression model was used to examine demographic and clinical characteristics associated with PIMs. Health care utilization rates and costs were also analyzed and compared between patients with and without PIMs using generalized linear models. All models included dummy variables indicating age category, female sex, hospitalization, polypharmacy, index month, and number of Elixhauser comorbidities to adjust for potential confounders. RESULTS Among 6628 elderly patients, 71.2% (4721/6628) were female and 62.9% (4167/6628) were aged 65 to 74 years; 43.6% (2889/6628) were prescribed at least one PIM. The most commonly used PIMs were histamine-2 blockers (20.5% [1356/6628]), benzodiazepines (11.4% [756/6628]), and anticholinergics and antihistamines (7.9% [526/6628]). No significant differences in incidence rates were observed based on age or sex. Inpatient service use, polypharmacy, and comorbidities of peptic ulcer, depression, and cardiac arrhythmias were significant predictors of PIM use while controlling for other factors. PIM users had significantly higher hospitalization risk (1.68-fold), more outpatient visit days (1.18-fold), and higher medical costs (33% increase) than did nonusers. CONCLUSIONS In a group of elderly Japanese patients, 43.6% used at least one PIM over a 1-year period in this study. PIM use was associated with greater health care utilization rates and costs.
British Journal of Cancer | 2009
Takeru Shiroiwa; Takashi Fukuda; Kiichiro Tsutani
Background The objective of this review was to summarize findings on aquatic exercise and balneotherapy and to assess the quality of systematic reviews based on randomized controlled trials. Methods Studies were eligible if they were systematic reviews based on randomized clinical trials (with or without a meta-analysis) that included at least 1 treatment group that received aquatic exercise or balneotherapy. We searched the following databases: Cochrane Database Systematic Review, MEDLINE, CINAHL, Web of Science, JDream II, and Ichushi-Web for articles published from the year 1990 to August 17, 2008. Results We found evidence that aquatic exercise had small but statistically significant effects on pain relief and related outcome measures of locomotor diseases (eg, arthritis, rheumatoid diseases, and low back pain). However, long-term effectiveness was unclear. Because evidence was lacking due to the poor methodological quality of balneotherapy studies, we were unable to make any conclusions on the effects of intervention. There were frequent flaws regarding the description of excluded RCTs and the assessment of publication bias in several trials. Two of the present authors independently assessed the quality of articles using the AMSTAR checklist. Conclusions Aquatic exercise had a small but statistically significant short-term effect on locomotor diseases. However, the effectiveness of balneotherapy in curing disease or improving health remains unclear.
PharmacoEconomics | 2009
Ataru Igarashi; Hiroki Takuma; Takashi Fukuda; Kiichiro Tsutani
Traditional Japanese medicine, Kampo, is used by over 80% of medical doctors in Japan. Owing to its high quality and safety, Kampo has been integrated into modern medicine, and there are 345 randomized controlled trials using Kampo in Japan as of 2010. Although there are a number of articles in top journals about basic science research, we can find only small numbers of high-quality clinical evidence. Since undergraduate education on Kampo has been established, integrative approach with the balanced combination of modern medicine and Kampo is expected to generate good clinical evidence in the near future.
International Journal of General Medicine | 2011
Hiroharu Kamioka; Kiichiro Tsutani; Yoshiteru Mutoh; Hiroyasu Okuizum; Miho Ohta; Shuichi Handa; Shinpei Okada; Jun Kitayuguchi; Masamitsu Kamada; Nobuyoshi Shiozawa; Sang-Jun Park; Takuya Honda; Shoko Moriyama
Background and objective: ‘Drug lag’ was a much‐debated issue around the world during the 1970s and 1980s. Because public recognition of drug lag is recent in Japan, the issue has not been studied extensively. Therefore, we created a database of new drug approvals in the US, the European Union (EU) and Japan between 1999 and 2007 and examined the drug lag situation in these three major pharmaceutical markets.